Enterprise Value
255.9M
Cash
151.7M
Avg Qtr Burn
-11.65M
Short % of Float
19.80%
Insider Ownership
2.02%
Institutional Own.
60.74%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PDUFA Approval decision | ||
ADX-2191 (methotrexate injection (DHFR inhibitor)) Details Eye disease , Proliferative vitreoretinopathy, Rare diseases, Primary Vitreoretinal Lymphoma, Retinitis Pigmentosa | NDA FDA meeting | |
Reproxalap (ADX-102) Details Rare diseases, Rare genetic disease, Allergic conjunctivitis | Phase 3 Update | |
ADX-629 Details Sjögren-Larsson Syndrome | Phase 2 Data readout | |
ADX-629 Details Chronic cough | Phase 2 Update | |
ADX-629 Details Alcoholic hepatitis | Phase 2 Initiation | |
ADX-629 Details Idiopathic Nephrotic Syndrome | Phase 2a Data readout | |
ADX-629 Details Atopic dermatitis | Phase 2a Data readout |